In a filing, Verona Pharma Plc ADR revealed its President and CEO ZACCARDELLI DAVID unloaded Company’s shares for reported $3.21 million on Dec 05 ’24. In the deal valued at $5.01 per share,640,264 shares were sold. As a result of this transaction, ZACCARDELLI DAVID now holds 14,367,552 shares worth roughly $928.86 million.
Then, ZACCARDELLI DAVID sold 162,800 shares, generating $815,400 in total proceeds. Upon selling the shares at $5.01, the President and CEO now owns 14,204,752 shares.
Before that, ZACCARDELLI DAVID sold 67,608 shares. Verona Pharma Plc ADR shares valued at $338,162 were divested by the President and CEO at a price of $5.00 per share. As a result of the transaction, ZACCARDELLI DAVID now holds 15,007,816 shares, worth roughly $970.26 million.
ROTH MKM initiated its Verona Pharma Plc ADR [VRNA] rating to a Buy in a research note published on January 10, 2025; the price target was $68. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in early October with a ‘”an Overweight”‘ rating.
Price Performance Review of VRNA
On Friday, Verona Pharma Plc ADR [NASDAQ:VRNA] saw its stock fall -1.55% to $64.65. Over the last five days, the stock has lost -7.15%. Verona Pharma Plc ADR shares have risen nearly 39.21% since the year began. Nevertheless, the stocks have risen 281.19% over the past one year. While a 52-week high of $70.40 was reached on 03/03/25, a 52-week low of $11.39 was recorded on 01/10/25. SMA at 50 days reached $56.60, while 200 days put it at $34.55.
Levels Of Support And Resistance For VRNA Stock
The 24-hour chart illustrates a support level at 62.62, which if violated will result in even more drops to 60.58. On the upside, there is a resistance level at 67.10. A further resistance level may holdings at 69.54. The Relative Strength Index (RSI) on the 14-day chart is 55.25, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.22, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 70.29%. Stochastics %K at 48.77% indicates the stock is a holding.
The most recent change occurred on August 26, 2022 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $31 price target.
